Contract 75A50120C00169
Locus Biosciences Inc · Department Of Health And Human Services · September 28, 2020
Locus Biosciences Inc was awarded a federal contract by Department Of Health And Human Services (Office Of Assistant Secretary For Preparedness And Response) on September 28, 2020 for $29.01 million of work in research and development in biotechnology (except nanobiotechnology). Performance is in Morrisville, NC. It was awarded under full and open competition. The contract has been modified 3 times since the base award It uses cost sharing contract pricing. The most recent modification was on September 16, 2025. If all options are exercised, the contract could reach $109.82 million.
Contract details
- PIID
- 75A50120C00169
- Award type
- Definitive Contract
- Pricing
- Cost Sharing
- Set-aside
- No Set Aside Used.
- Competition
- Full And Open Competition
- NAICS
- 541714 · Research And Development In Biotechnology (Except Nanobiotechnology)
- Product / service
- Health R&D Services; Health Care Services; Experimental Development
- Place of performance
- Morrisville, NC
- First action
- September 28, 2020
- Latest action
- September 16, 2025
Description
THE PURPOSE OF THIS BILATERAL MODIFICATION IS TO: 1. ADD $14,773,583.00 OF SUPPLEMENTAL FUNDING TO CLIN 0002. 2. ADD $3,226,417.00 OF SUPPLEMENTAL FUNDING TO CLIN 0003.
Modification timeline
-
September 16, 2025Mod P00009 · Funding Only Action$73.89M
-
September 27, 2022Mod P00005 · Other Administrative ActionTHE PURPOSE OF THIS NO COST, BILATERAL MODIFICATION IS TO: A.) UPDATE ARTICLE B.2, BASE PERIOD TO UPDATE THE POP OF CLIN 0001. B.) THE PERIOD OF PERFORMANCE FOR CLIN 0001 (BASE PERIOD) IS EXTENDED F…$48.95M
-
September 9, 2021Mod P00002 · Change OrderADVANCE THE DEVELOPMENT OF CRPHAGE AS A CRISPR-ENGINEERED PRECISION ANTIBACTERIAL OF URINARY TRACT INFECTIONS CAUSED BY E. COLI.$48.95M
-
September 28, 2020Base awardCLINICAL DEVELOPMENT OF CRISPR-CAS3 PHAGE COCKTAIL FOR THE TREATMENT OF RECURRENT URINARY TRACT INFECTIONS CAUSED BY ESCHERICHIA COLI INCLUDING ANTIMICROBIAL AND MULTI-DRUG RESISTANT STRAINS$48.95M
Similar contracts
| Recipient | Agency | Date | Obligated |
|---|---|---|---|
| Vericel Corporation | Department Of Health And Human Services | April 1, 2026 | $34.88M |
| American College Of Medical Toxicology, Inc. | Department Of Health And Human Services | March 31, 2026 | $0 |
| Ceramedix Holding, Llc | Department Of Health And Human Services | March 31, 2026 | $4.22M |
| Glaxosmithkline, Llc | Department Of Health And Human Services | March 31, 2026 | $7.79M |
| Care Access Research Llc | Department Of Health And Human Services | March 31, 2026 | $2.55M |
| Pattern Bioscience, Inc. | Department Of Health And Human Services | March 31, 2026 | $22.50M |
Top contractors in NAICS 541714
Lifetime obligated dollars across all federal contracts in this NAICS code.
| # | Contractor | Contracts | Obligated |
|---|---|---|---|
| 1 | Amgen USA Inc | 1 | $59.99M |
| 2 | Vericel Corporation | 1 | $34.88M |
| 3 | Spectral Md, Inc. | 1 | $31.67M |
| 4 | Ppd Development Lp | 6 | $31.12M |
| 5 | L3 Technologies, Inc. | 1 | $22.00M |
| 6 | Technical Resources International, Inc. | 6 | $21.80M |
| 7 | Abbott Laboratories | 1 | $21.01M |
| 8 | Paratek Pharmaceuticals, Inc | 1 | $17.47M |
| 9 | Ossium Health, Inc. | 1 | $12.39M |
| 10 | Rho Federal Systems Division Inc | 1 | $8.00M |
Track this on BesaGov
Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.
Continue learning
Keep researching
Frequently asked questions
What is contract 75A50120C00169?
Contract 75A50120C00169 is a federal contract awarded to Locus Biosciences Inc by Department Of Health And Human Services on September 28, 2020 for $29.01 million of work classified under RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY). It has been modified 3 times since the base award.
Who won contract 75A50120C00169?
Locus Biosciences Inc won contract 75A50120C00169 from Department Of Health And Human Services.
How much is contract 75A50120C00169 worth?
Contract 75A50120C00169 has obligated $29.01 million to date, with a total potential value of $109.82 million if all options are exercised.